ICICI Prudential Mutual Fund decreased its stake in Gufic Biosciences from 2.12% to 2.02%, selling 95,840 shares worth ₹3.66 Cr.
A pharmaceutical manufacturer engaged in producing medicinal chemicals, botanical products, and finished pharmaceutical formulations for domestic and international markets. Gufic BioScience operates across multiple therapeutic segments, focusing on research-driven drug development and manufacturing of active pharmaceutical ingredients. The company combines traditional botanical expertise with modern pharmaceutical science to deliver diverse healthcare solutions across different treatment areas.
India's second-largest AMC by AUM with over Rs 9 lakh crore managed across 80+ schemes. Joint venture between ICICI Bank and Prudential plc. CIO S. Naren is one of India's most recognised value investors, known for contrarian macro calls and rotating across market caps well ahead of consensus. ICICI Pru's quarterly portfolio disclosures are among the most closely watched in the industry.
